Wellington Management Group LLP Sells 1,148,356 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Wellington Management Group LLP lessened its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 73.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 423,039 shares of the company's stock after selling 1,148,356 shares during the period. Wellington Management Group LLP owned 0.91% of Omnicell worth $18,444,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OMCL. Nisa Investment Advisors LLC increased its position in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock valued at $38,000 after acquiring an additional 1,000 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. CWM LLC increased its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company's stock valued at $83,000 after purchasing an additional 1,236 shares in the last quarter. 1620 Investment Advisors Inc. raised its position in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Omnicell during the 2nd quarter worth $104,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

OMCL traded up $0.05 during midday trading on Friday, reaching $46.01. 296,981 shares of the company were exchanged, compared to its average volume of 535,995. The stock has a market capitalization of $2.13 billion, a P/E ratio of -117.97, a PEG ratio of 35.72 and a beta of 0.77. The stock's 50-day simple moving average is $45.32 and its 200 day simple moving average is $38.99. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74.

Insider Activity

In other news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.64% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OMCL. Bank of America reissued a "neutral" rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Wells Fargo & Company raised their price target on Omnicell from $30.00 to $41.00 and gave the company an "equal weight" rating in a report on Monday, October 14th. StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday. Benchmark restated a "buy" rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $52.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.